Non-ownership Filings
| Enhertu approved in US for breast cancer post ET | Jan. 28, 2025 |
| Dato-DXd approved in US for HR+ breast cancer | Jan. 20, 2025 |
| Calquence combination approved in US for 1L MCL | Jan. 17, 2025 |
| Total Voting Rights | Jan. 02, 2025 |
| Dato-DXd NSQ NSCLC application withdrawn in EU | Dec. 24, 2024 |
| Tagrisso approved in EU based on LAURA trial | Dec. 23, 2024 |
| Imfinzi approved in US for limited-stage SCLC | Dec. 05, 2024 |
Ownership Update Filings
| Director/PDMR Shareholding | Nov. 20, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |
| Director/PDMR Shareholding | Nov. 13, 2024 |
| Director/PDMR Shareholding | Jun. 12, 2024 |
| Director/PDMR Shareholding | May. 15, 2024 |
| Director/PDMR Shareholding | Mar. 12, 2024 |